To identify factors contributing to the variation in weight loss after Roux-en-Y gastric bypass (RYGB). DESIGN: Cross-sectional study of patients with good (excess body mass index lost (EBL) 460%) and poor weight loss response (EBL o50%) 412 months after RYGB and a lean control group matched for age and gender. MATERIALS AND METHODS: Sixteen patients with good weight loss response, 17 patients with poor weight loss response, and eight control subjects were included in the study. Participants underwent dual energy X-ray absorptiometry scan, indirect calorimetry and a 9 h multiple-meal test with measurements of glucose, insulin, total bile acids (TBA), glucagon-like peptide (GLP)-1, peptide YY 3-36 (PYY), cholecystokinin (CCK), ghrelin, neurotensin and pancreatic polypeptide (PP) as well as assessment of early dumping and appetite. RESULTS: Suppression of hunger was more pronounced in the good than the poor responders in response to the multiple-meal test (P ¼ 0.006). In addition, the good responders had a larger release of GLP-1 (P ¼ 0.009) and a greater suppression of ghrelin (P ¼ 0.037) during the test, whereas the postprandial secretion of CCK was highest in the poor responders (P ¼ 0.005). PYY, neurotensin, PP and TBA release did not differ between the RYGB-operated groups. Compared with control subjects, patients had exaggerated release of GLP-1 (Po0.001), PYY (P ¼ 0.008), CCK (P ¼ 0.010) and neurotensin (Po0.001). Early dumping was comparable in the good and poor responders, but more pronounced than in controlled subjects. Differences in resting energy expenditure between the three groups were entirely explained by differences in body composition. CONCLUSION: Favorable meal-induced changes in hunger and gut hormone release in patients with good compared with poor weight loss response support the role of gut hormones in the weight loss after RYGB.
INTRODUCTION
Roux-en-Y gastric bypass (RYGB) induces a weight loss of 25-30% of total body weight, which attains a nadir after 12-18 months and is maintained in most patients for at least 10 years after surgery. 1 However, the degree of weight loss after RYGB varies considerably and 10-20% of patients undergoing the procedure experience a relative poor response (often defined as a maximal excess BMI (body mass index) lost (EBL) of o50%).
2,3
The mechanisms responsible for weight loss after RYGB are incompletely understood, but postoperative changes in appetite and energy intake, rather than nutrient malabsorption, seem to have a crucial role. 4 After the operation, reduced hunger combined with early and prolonged satiety after food intake are reported, 5, 6 resulting in reduced meal size without compensatory increase in meal frequency. In addition, there may be preference for less energy-dense foods. [7] [8] [9] Several factors have been related to the reduction in appetite and energy intake after RYGB. Early dumping, including nausea, abdominal pain and palpitations occurring within the first hour after meal ingestion in response to high-carbohydrate or high-fat meals, 10 may promote a negative conditioning to energy-dense foods, for example, candies and soft drinks. 7, 11 Avoidance of energy-dense foods may, however, also be related to changes in taste perception and cerebral taste-reward networks. 12, 13 Another factor seems to be the surgery-induced alterations in the release of appetite regulating gut hormones. 6, 14 Thus, it has consistently been shown that the secretion of the anorexigenic hormones, glucagon-like peptide (GLP)-1 and peptide YY (PYY) , is increased after RYGB, 15 while the plasma concentration of ghrelin, the only known appetite-inducing hormone, is reduced during the first months after surgery, but later increases along with the reduction in body weight. 16, 17 Secretion of cholecystokinin (CCK), another anorexigenic hormone, was also increased after RYGB in the two studies where this was measured. 14, 18 In addition to reduced energy intake, it has been suggested that a relative increase in energy expenditure after RYGB could also contribute to weight loss, possibly due to alterations in gut hormone release 19 or changed recirculation of bile acids. 20, 21 In the present study, we describe gut hormone and bile acid secretion, appetite, early dumping and resting energy expenditure (REE) in two groups of weight stable RYBG-operated patients, one with a poor and one with a good postoperative weight loss response, in order to identify factors influencing weight loss after RYGB. We also compared the patients with a group of lean control subjects.
MATERIALS AND METHODS

Subjects and study design
Patients with uncomplicated RYGB at Hvidovre Hospital (Hvidovre, Denmark) 412 months earlier, a postoperative EBL at the time of the study of p50% (poor weight loss responders) or X60% (good weight loss responders), and stable body weight during the last 3 months before examination (±5 kg of total body weight) were invited to participate. Patients were excluded if they had undergone other bariatric surgery before RYGB, had any disease known to affect appetite and intestinal motility, had a fasting plasma glucose X6.1 mmol l À 1 , or were taking antidiabetic medication at the time of the study. RYGB surgery had been performed as described earlier. 22 Lean control subjects matched for gender and age were recruited through announcements in local newspapers. A written informed consent was obtained from all participants, and the study was approved by the Municipal Ethical Committee of Copenhagen in accordance with the Helsinki-II declaration and by the Danish Data Protection Agency and was registered at www.clinicaltrials.gov (ClinicalTrials.gov ID NCT00908973).
All participants underwent indirect calorimetry, dual energy X-ray absorptiometry (DEXA) scan and a multiple-meal test.
Indirect calorimetry REE was measured in the morning after an overnight fast (10 h) using a canopy system (Deltatrac II Metabolic Monitor, Datex-Ohmeda, Helsinki, Finland). After an initial 15 min resting period in a quiet environment with participants in a supine position, CO 2 production and O 2 consumption were determined during a 40 min period. REE was calculated using the median oxygen uptake ( . V O2 ) and carbon dioxide output ( .
. 23 Calibration was performed periodically according to manufacturers' instructions.
Body weight and DEXA
On the same day as the indirect calorimetry, body weight was recorded and a DEXA scan was performed, using a Hologic Discovery A (S/N 83487) DEXA scanner (Hologic Inc., Bedford, MA, USA) with software package Apex 2.3, to determine fat mass (FM) and fat free mass (FFM).
Multiple-meal test At 8.00a.m. after an overnight fast (10-12 h), participants were placed resting in a recumbent position while a cannula was inserted in a cubital vein for blood sampling. At B9.00a.m. the first meal, a 120 g egg omelette with 80 g white bread (comprising a total of 400 kcal with 22% protein, 43% carbohydrate and 35% fat) was consumed. Three hours later the second meal, consisting of two pieces of black bread, one with butter, egg, tomato, mayonnaise and shrimps and one with pâte and cucumber (297 kcal with 15% protein, 36% carbohydrate and 49% fat), was consumed, followed after another 3 h by the last meal, a vanilla-pudding (273 kcal with 15% protein, 55% carbohydrate and 30% fat). All meals were consumed over a period of 15 min accompanied by 250 ml of water. Participants also drank 200 ml of water 90 min after each meal. Venous blood was drawn 10 and 0 min before and 15, 30, 45, 60, 90, 120 and 180 min after each meal and collected into clot activator tubes for insulin analysis, and into chilled EDTA tubes for analysis of ghrelin, GLP-1, PYY, CCK, neurotensin, pancreatic polypeptide (PP), and total bile acids (TBA). Clot activator tubes were left to coagulate for a minimum of 20 min, whereas EDTA tubes were immediately centrifuged at 4 1C. Until analysis serum was stored at À 80 1C and plasma at À 20 1C. During the test, patients were sitting upright or walking about slowly. No strenuous activity was allowed. After 9 h patients were discharged.
VAS score and peripheral pulse VAS-scoring for hunger and satiety was performed 10 and 0 min before and at 30 min-intervals after each meal. At the same time-intervals after the third meal, VAS-scoring for nausea and abdominal pain was performed. The VAS-scores were 100 mm with a text expressing the most positive and the most negative rating anchored at each end. Participants could not compare with previous ratings or discuss their ratings with others. During the third meal, peripheral pulse rates were measured using a handheld pulse oximeter (Nellcor NPB-40, Covidien, Dublin, Ireland). The participants rested for at least 5 min before each pulse measurement.
Biochemical analysis
Plasma glucose concentrations were measured immediately using a HemoCue Glucose 201 analyzer (HemoCue AB, Ä ngelholm, Sweden). Serum insulin concentrations were determined by Immulite 2000 analyzer (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA). Plasma samples for GLP-1, PP and neurotensin measurements were extracted with ethanol (70% final concentration) before analysis. Total GLP-1 was assayed as described previously, 24 using a radioimmunoassay (RIA, antiserum no. 89390) specific for the C-terminal of the GLP-1 molecule and reacting equally with intact GLP-1 and the primary (N-terminally truncated) metabolite. PP was measured using a mid-region specific antibody, code no. HYB 347-07 (Statens Serum Instiut, Copenhagen, Denmark). For standards we used human PP and the tracer was 125 I-labeled human PP, cat. no. NEX315 (Perkin Elmer, Boston, MA, USA). Neurotensin was measured with an in-house RIA using a C-terminal specific antibody, code no. 3844 (generous gift from Professor Jan Fahrenkrug, Bispebjerg Hospital, Copenhagen, Denmark). For standards we used neurotensin cat. no. H-4435 (Bachem, Bubendorf, Switzerland) and the tracer was 125 I-labeled neurotensin, labeled using the standard stoichiometric chloramine T method. The assay shows o0.1% cross-reaction with neuromedin N. Ghrelin and peptide YY were quantified using commercial RIA-kits (LINCO Research, St Charles, MO, USA). For both assays, standard curves were similar to those provided by the manufacturers and all quality controls were within prespecified limits. CCK was measured with a RIA where the antiserum (no. 92128) binds the bioactive forms of CCK with equal potency without cross-reactivity with any gastrin. 25, 26 TBA concentrations were measured using an enzyme cycling based TBA assay kit, cat. no. DZ042A-K (Diazyme, San Diego, CA, USA). The assay was performed according to the manufacturer's protocol and quality controls were within acceptable range.
Statistical analysis and calculations
Data are expressed as mean ± s.e. of the mean (s.e.m.) if not otherwise specified. Incremental areas under the curves (iAUCs) were calculated using the trapezoidal model and subtraction of fasting values. EBL was calculated using the formula (preoperative BMI À study BMI)/(preoperative BMI À 25) Â 100%. Homeostatic model assessment 2 of insulin resistance (HOMA2-IR) was calculated using the spreadsheet available from www.OCDEM.ox.ac.uk. 27 Pre-meal hunger was calculated from the VASscores as the mean of two scores performed within the last 10 min before each meal and postmeal satiety was calculated as the mean VAS-score during the first 60 min after each meal.
Comparisons between good and poor responders as well as between patients and control subjects were performed using unpaired t test if not otherwise specified. For the latter comparison, data from the good and poor responders was pooled. The frequency of early dumping was compared using w 2 test. Comparison of REE adjusted for FFM and FM was performed using a linear regression model with REE as dependent variable and group, FFM and FM as independent variables. Po0.05 was considered significant. Analyses were performed in R version 2.14.1 (www. R-project.org/).
RESULTS
Subjects
Thirty-three patients, 16 good (11 women and 5 men, 47.8±2.1 years, time from surgery 19.2±0.8 months) and 17 poor weight loss responders (13 women and 4 men, 48.2 ± 2.1 years of age, 18.7 ± 0.8 months), as well as eight control subjects (five women and three men, 48.2±2.9 years of age) were included. Three patients, one good and two poor responders, did not complete the multiple-meal test; one had a high fever on the day of the study, one failed to consume the meals in concordance with the protocol and one was not fasting on the day of the study. Furthermore, one poor responder did not complete the indirect calorimetry and DEXA scan.
Body weight and composition Preoperatively, the good responders had a lower BMI than the poor (42.3 ± 0.9 kg m À 2 versus 46.4 ± 1.2, P ¼ 0.009) and by the time of the study the weight loss (EBL) in the good responders was 85.8±4.5% (range 60.6-124.9) versus 35.0±1.7% (20.1-48.5) in the poor (Po0.001), in accordance with the study' inclusion criteria. BMI, body weight and body composition at the time of the study are shown in Table 1 .
Glucose, insulin and TBA Fasting and postprandial concentrations of glucose, insulin and TBA are shown in Table 2 and Figures 1a-c, respectively. In response to the multiple-meal test, patients had an earlier rise in plasma glucose and, except for the first meal, reached higher glucose peak concentrations than control subjects (1st meal: patients 7.02±0.16 mmol l À 1 versus control subjects 7.23±0.31, P ¼ 0.562; 2nd meal: 7.26 ± 0.13 versus 6.51 ± 0.13, P ¼ 0.006; 3rd meal: 10.16 ± 0.28 versus 8.30 ± 0.36, P ¼ 0.003). Likewise, insulin secretion increased earlier after the meals and reached higher peak concentrations in the patients than the control subjects, with the highest peak insulin concentrations in the poor responders (1st meal: good 167 ± 26 pmol l À 1 versus poor 257 ± 20, P ¼ 0.012; Table 2 and iAUCs in Figure 2 . Fasting GLP-1 levels did not differ, but in response to the multiple-meal test the good responders had greater GLP-1 releases than the poor. Moreover, postprandial GLP-1 release in the patients was much higher than in control subjects. Fasting and postprandial PYY levels did not differ between the good and poor responders, but were higher than in control subjects. Fasting CCK levels did not differ between the groups, although patients tended to have lower levels than control subjects. However, postprandial CCK release was higher in the poor than the good responders, and higher in patients than control subjects. Fasting ghrelin levels were lowest in the poor responders and highest in control subjects, whereas suppression of ghrelin during the multiple-meal test was larger in the good responders than the poor. Fasting and postprandial neurotensin concentrations did not differ between the operated groups, but compared with control subjects fasting neurotensin concentrations were lower and postprandial release higher. PP concentrations did not differ between the groups either at fasting or postprandially. Mechanisms of weight loss after gastric bypass C Dirksen et al multiple-meal test premeal hunger, that is, the level of hunger just prior to food intake, gradually declined in the good, but not in the poor responders or control subjects (Figure 3a) . This resulted in a significantly larger reduction in hunger by the end of the multiplemeal test in the good than the poor responders ( À 13±5 mm versus 8 ± 6, P ¼ 0.006). Postmeal satiety, that is, the satiety during the first 60 min after meal intake, did not differ between the three groups ( Figure 3b ).
Early dumping Changes in nausea, abdominal pain and peripheral pulse rate within the first hour after ingestion of the third meal are shown in Figure 4 . Nine of 15 (60%) good responders reported an increase of 45 mm in nausea compared with 7 of 15 (47%) poor responders (P ¼ 0.715) and 1 of 8 (13%) control subjects (P ¼ 0.053). One (7%) good responder reported an increase of 45 mm in abdominal pain compared with three (20%) poor responders (P ¼ 0.598) and one (13%) control subject (P ¼ 1.000). An increase in peripheral pulse rate 410 beats per min, which is an indicator of early dumping, 10 was observed in 10 of 15 (67%) good responders, 10 of 14 (71%) poor responders (P ¼ 1.000) and 1 of 8 (13%) control subjects (P ¼ 0.012).
REE REE was highest in the poor responders and lowest in control subjects (good 1614±58 kcal per day, poor 1828±58, P ¼ 0.015 and control 1457 ± 48, P ¼ 0.010), but adjusted for FFM and FM using a linear regression model, no differences was found between the good and poor responders (P ¼ 0.564) or between patients and control subjects (P ¼ 0.756). In the model FFM increased REE by 17.8 kcal per day per kg (Po0.001), while the effect of FM was 2.2 kcal per day per kg (P ¼ 0.457).
DISCUSSION
We identified patients with good and poor postoperative weight loss response 412 months after surgery, a time when maximal weight loss is usually attained. 1 The good weight loss responders distinguished themselves from the poor by improved suppression of premeal hunger, increased release of GLP-1 and more pronounced suppression of ghrelin in response to the multiplemeal test, while REE and early dumping did not differ.
A substantial reduction in appetite early after RYGB that persists for months to years is well established, 5, 6, 28, 29 but we are to our knowledge the first to relate a quantitative measure of appetite, that is, VAS scores, directly to different degrees of postoperative weight loss. Our results show that during the multiple-meal test premeal hunger decreased gradually in the good responders, while no change was seen in the poor. Considering that RYGBpatients are instructed to eat frequently, 30 a prolonged suppression of hunger after meals is likely to influence food intake and thus contribute to weight loss.
Appetite reduction and weight loss after RYGB have been related to postoperative changes in meal-induced release of hormones from the enteroendocrine cells in the gut, 6, 14 and in our study the good responders had a more anorectic postprandial gut hormone profile. In line with our findings, le Roux et al. 6 reported increased release of GLP-1 and PYY in patients with a good compared with a poor postoperative weight loss response 2 years after RYGB. Both of these hormones reduce appetite and food intake during infusion, 31, 32 and interestingly this effect is additive during coinfusion. 33, 34 We also found decreased fasting neurotensin in patients compared with control subjects, which is conflicting with previous reports, 35, 36 but these studies measured proneurotensin and not active neurotensin. Postprandial active neurotensin was exaggerated in patients compared with control subjects, and in patients, the secretion profile was rather similar to that of GLP-1, suggestive of common mechanisms of secretion. 37 In line with previous studies, 14, 18 postprandial CCK secretion was elevated in patients compared with control subjects, but unexpectedly also elevated in the poor compared with the good responders. However, it has been proposed that the appetite regulating role of CCK is primarily mediated via afferent vagal nerves from the gut, thus circulating concentrations, which are generally low, may be a less accurate measure of the satiety signal from this hormone. 38 Fasting ghrelin was lowest in the poor responders and highest in control subjects as expected from the differences in BMI 39 and in agreement with previous findings in long-term studies of RYGB operated patients. 16, 17, 29, 40, 41 Interestingly, however, the suppression of ghrelin during the multiple-meal test was most pronounced in the good responders. Postprandial suppression of ghrelin is attenuated in obese compared with lean individuals, 39, 42, 43 but has been shown to be restored 1 year after RYGB 18 and is comparable to that of lean controls 2-3 years after surgery. 43, 44 In addition, ghrelin receptor polymorphism has been shown to influence the degree of weight loss achieved after RYGB, perhaps through a reduction in the expression of the growth hormone secretagogue receptor type 1 causing lower ghrelin signaling and hence a reduction in appetite. 41 The release of PP did not differ between the groups in our study, although a slightly and insignificantly lower postprandial secretion seemed to be present in the RYGBoperated patients, which is in accordance with a previous crosssectional study 42 years after RYGB. 36 Thus, mild impairment of vagal function after RYGB cannot be ruled out, 45 but does not appear to be essential for postoperative weight loss. Fasting TBA increase after RYGB, 20, 21 and in agreement, we found threefold elevated fasting TBA in patients compared with control subjects. Further, the increase in postprandial bile acid concentrations tended to be larger in patients than control subjects, especially in response to the second and third meal. Bile acids have been associated with increase in whole-body energy expenditure and improved glucose metabolism. 46 Furthermore, in animals, activation of the bile acid receptor TGR5 induces GLP-1 release from the intestinal L cells 47 and drainage of bile directly into the ileum is associated with increased release of GLP-1 and PYY. 21 Taken together, increased postprandial release of GLP-1 and PYY combined with an enhanced suppression of ghrelin is likely to be a powerful anorectic gut-brain signal that could explain the difference in appetite between the good and poor weight loss responders. Altered bile acid recirculation could contribute to the differences in gut hormone release, but no firm conclusions can be drawn based on our findings. The roles of neurotensin, CCK and PP clearly need further exploration, but based on our results they do not seem to have a major role for the postoperative weight loss.
Early dumping has been suggested to contribute to the postoperative weight loss through a conditioned aversion for energy dense foods like fats and candies. 7, 11 We evaluated early dumping using VAS scores and an increase in peripheral pulse rate 410 beats per min within the first postprandial hour, which has been reported to be a sensitive and specific indicator of early dumping. 10 In accordance with one previous study, 48 early dumping was more frequent in patients than control subjects, while the two groups of patients did not differ, suggesting that early dumping does not have any crucial role for the degree of weight loss obtained after the operation.
We did not find any difference in REE between the three study groups when adjusting for FFM and FM. The contribution of FFM to REE in our model was comparable to that previously reported, 49 while only a minor and insignificant contribution from FM was seen. Thus, REE does not explain the difference in weight loss observed in our study. However, REE is highly related to body composition and accounts for only about 2/3 of total energy expenditure with the remainder being accounted for by mealinduced thermogenesis and physical activity, 50 which we did not study. From animal studies, it has been suggested that mealinduced thermogenesis rather than REE is increased after RYGB, 19 but this has not been demonstrated in humans. 50 Glucose tolerance was comparable in the two groups of patients with no difference in fasting and postprandial glucose concentrations, but insulin resistance measured by HOMA2-IR was twice as high in the poor compared with the good responders. This difference in insulin resistance may explain the increased postprandial insulin secretion in the poor responders despite lower GLP-1 release, since increased insulin secretion is a wellknown adaptive response to reduced insulin sensitivity in individuals with normal glucose tolerance. 51 Our study has some limitations. We used a multiple-meal test consisting of three mixed meals with different texture and macronutrient composition and duration of 9 h. This test allows examination of the accumulated effects of the meals, which is likely to be of importance during daily living because RYGB patients are instructed to eat frequently. 30 Unfortunately this also makes comparison of the isolated meals complicated despite obvious differences in the impact of the meals on appetite, glucose homeostasis and gut hormone secretion. Furthermore, our design was cross-sectional without presurgical data except for body weight, thus it is not possible to know whether differences between the surgical groups actually preceded the weight loss or are merely a consequence of the difference in body weight at the time of the study. Control subjects were lean and matched for age and gender, but whether matching for either preoperative or actual BMI of the patients would have yielded similar results cannot be answered by this study. Lean control subjects were chosen to serve as normal reference as gut hormone responses are influenced by obesity. We studied a broad range of mechanisms proposed or known to influence weight loss, but many other important factors were not explored including genetic disposition, level of physical activity, socio-economic status and eating habits.
In conclusion, successful weight loss response after RYGB was not associated with early dumping nor with increased REE, but rather with an improved suppression of premeal hunger, probably explained by gut hormone release favoring an anorectic state, including increased release of GLP-1 and improved suppression of ghrelin. These results should be encouraging for the continuous efforts to develop gut hormone based pharmacological therapies mimicking the effects of RYGB on appetite and body weight. 
